Comparative community outreach to increase cervical cancer screening in the Mississippi Delta

Preventive Medicine

Volumn 52, Issue 6, 2011, Pages 452-455

  Castle, Philip E ^a,b   Rausa, Alfio ^c   Walls, Tameka ^d   Gravitt, Patti E ^e   Partridge, Edward E ^f   Olivo, Vanessa ^d   Niwa, Shelley ^d   Morrissey, Kerry Grace ^d   Tucker, Laura ^c   Katki, Hormuzd ^a   Scarinci, Isabel ^f,g  

^a NATIONAL CANCER INSTITUTE   (United States)

^b American Society for Clinical Pathology   (United States)

^c MISSISSIPPI STATE DEPARTMENT OF HEALTH   (United States)

^d WESTAT   (United States)

^e JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^g University of Alabama at Birmingham   (United States)

Author keywords

Atypical squamous cells of undetermined significance (ASC US); Cervical cancer; Cervical cancer screening; Cervical intraepithelial neoplasia (CIN); Health disparities; Human papillomavirus (HPV); Hybrid Capture 2 (HC2); Pap

Indexed keywords

VIRUS DNA;

ADULT; ARTICLE; CANCER SCREENING; COMMUNITY CARE; COMPARATIVE STUDY; FEASIBILITY STUDY; FEMALE; GROUPS BY AGE; HEALTH CARE COST; HIGH RISK POPULATION; HOME CARE; HOSPITAL CARE; HUMAN; MAJOR CLINICAL STUDY; NONHUMAN; PAPANICOLAOU TEST; PATIENT PARTICIPATION; PRIORITY JOURNAL; QUESTIONNAIRE; RACE DIFFERENCE; SAMPLING; SELF SAMPLING; UNITED STATES; UTERINE CERVIX CANCER; VIRUS EXAMINATION; WART VIRUS;

ADULT; AGED; COMMUNITY-INSTITUTIONAL RELATIONS; EARLY DETECTION OF CANCER; FEASIBILITY STUDIES; FEMALE; HUMANS; MASS SCREENING; MEDICALLY UNDERSERVED AREA; MIDDLE AGED; MISSISSIPPI; PAPILLOMAVIRIDAE; PATIENT ACCEPTANCE OF HEALTH CARE; REAGENT KITS, DIAGNOSTIC; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 79957887743     PISSN: 00917435     EISSN: 10960260     Source Type: Journal    
DOI: 10.1016/j.ypmed.2011.03.018     Document Type: Article

References (19)

1. Belinson J., Qiao Y., Pretorius R., Zhang W., Keaton K., Elson P., Fischer C., Lorincz A., Zahniser D., Wilbur D., Pan Q., Li L., Biscotti C., Dawson A., Li A., Wu L., Ling Y., Ma C.P., Yang X.P. Prevalence of cervical cancer and feasibility of screening in rural China: a pilot study for the Shanxi Province Cervical Cancer Screening Study. Int. J. Gynecol. Cancer 1999, 9:411-417.
2. Belinson J.L., Qiao Y.L., Pretorius R.G., Zhang W.H., Rong S.D., Huang M.N., Zhao F.H., Wu L.Y., Ren S.D., Huang R.D., Washington M.F., Pan Q.J., Li L., Fife D. Shanxi Province cervical cancer screening study II: self-sampling for high-risk human papillomavirus compared to direct sampling for human papillomavirus and liquid based cervical cytology. Int. J. Gynecol. Cancer 2003, 13:819-826.
3. Castle P.E., Aftab A., Saint-Jean G., Mendez L. Detection of carcinogenic human papillomavirus in specimens collected with a novel self-sampling device. J. Clin. Microbiol. 2006, 44:2158-2159.
4. Castle P.E., Sadorra M., Garcia F.A., Cullen A.P., Lorincz A.T., Mitchell A.L., Whitby D., Chuke R., Kornegay J.R. Mouthwash as a low-cost and safe specimen transport medium for human papillomavirus DNA testing of cervicovaginal specimens. Cancer Epidemiol. Biomarkers Prev. 2007, 16:840-843.
5. Castle P.E., Fetterman B., Poitras N., Lorey T., Shaber R., Kinney W. Five-year experience of human papillomavirus DNA and papanicolaou test cotesting. Obstet. Gynecol. 2009, 113:595-600.
6. Centers for Disease Control and Prevention (CDC) National, state, and local area vaccination coverage among adolescents aged 13-17years-United States, 2009. MMWR Morb. Mortal. Wkly. Rep. 2009, 59:1018-1023.
7. Freeman H.P. Patient navigation: a community based strategy to reduce cancer disparities. J. Urban Health 2006, 83:139-141.
8. Freeman, H.P. and Wingrove, B.K., 2007. Excess cervical cancer mortality: A marker for low access to health care in poor communities. 05-5282 ed. National Institutes of Health.
9. Garland S.M., Hernandez-Avila M., Wheeler C.M., Perez G., Harper D.M., Leodolter S., Tang G.W., Ferris D.G., Steben M., Bryan J., Taddeo F.J., Railkar R., Esser M.T., Sings H.L., Nelson M., Boslego J., Sattler C., Barr E., Koutsky L.A. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N. Engl. J. Med. 2007, 356:1928-1943.
10. Gok M., Heideman D.A., van Kemenade F.J., Berkhof J., Rozendaal L., Spruyt J.W., Voorhorst F., Belien J.A., Babovic M., Snijders P.J., Meijer C.J. HPV testing on self collected cervicovaginal lavage specimens as screening method for women who do not attend cervical screening: cohort study. BMJ 2010, 340:c1040. 10.1136/bmj.c1040, c1040.
11. Hildesheim A., Herrero R., Wacholder S., Rodriguez A.C., Solomon D., Bratti M.C., Schiller J.T., Gonzalez P., Dubin G., Porras C., Jimenez S.E., Lowy D.R. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 2007, 298:743-753.
12. McCredie M.R., Sharples K.J., Paul C., Baranyai J., Medley G., Jones R.W., Skegg D.C. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol. 2008, 9:425-434.
13. Ogilvie G., Krajden M., Maginley J., Isaac-Renton J., Hislop G., Elwood-Martin R., Sherlock C., Taylor D., Rekart M. Feasibility of self-collection of specimens for human papillomavirus testing in hard-to-reach women. CMAJ 2007, 177:480-483.
14. Paavonen J., Naud P., Salmeron J., Wheeler C.M., Chow S.N., Apter D., Kitchener H., Castellsague X., Teixeira J.C., Skinner S.R., Hedrick J., Jaisamrarn U., Limson G., Garland S., Szarewski A., Romanowski B., Aoki F.Y., Schwarz T.F., Poppe W.A., Bosch F.X., Jenkins D., Hardt K., Zahaf T., Descamps D., Struyf F., Lehtinen M., Dubin G., Greenacre M. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009, 374:301-314.
15. Scarinci I.C., Garcia F.A., Kobetz E., Partridge E.E., Brandt H.M., Bell M.C., Dignan M., Ma G.X., Daye J.L., Castle P.E. Cervical cancer prevention: new tools and old barriers. Cancer 2010.
16. Sowjanya A.P., Paul P., Vedantham H., Ramakrishna G., Vidyadhari D., Vijayaraghavan K., Laksmi S., Sudula M., Ronnett B.M., Das M., Shah K.V., Gravitt P.E. Suitability of self-collected vaginal samples for cervical cancer screening in periurban villages in Andhra Pradesh, India. Cancer Epidemiol. Biomarkers Prev. 2009, 18:1373-1378.
17. The FUTURE II Study Group Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N. Engl. J. Med. 2007, 356:1915-1927.
18. Wang S.S., Sherman M.E., Hildesheim A., Lacey J.V., Devesa S. Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white women and black women in the United States for 1976-2000. Cancer 2004, 100:1035-1044.
19. Wright T.C., Denny L., Kuhn L., Pollack A., Lorincz A. HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer. JAMA 2000, 283:81-86.